Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
11865 11735 12015 12085 12255 Last
537400 566200 1028200 805800 931700 Volume
-0.29% -1.10% +2.39% +0.58% +1.41% Change
Financials (JPY)
Sales 2020 761 B
EBIT 2020 285 B
Net income 2020 211 B
Finance 2020 409 B
Yield 2020 1,28%
Sales 2021 791 B
EBIT 2021 296 B
Net income 2021 220 B
Finance 2021 414 B
Yield 2021 1,44%
P/E ratio 2020 34,2x
P/E ratio 2021 30,2x
EV / Sales2020 8,28x
EV / Sales2021 7,96x
Capitalization 6 710 B
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (50.5% of net sales), bones and joints diseases treatment (34.3%), and kidney diseases (6.9%). Net sales are distributed geographically as follows: Japan (75.8%),... 
Sector
Pharmaceuticals
Calendar
03/30Shareholder meeting
More about the company
Surperformance© ratings of Chugai Pharmaceutical Co.,
Trading Rating : Investor Rating :
More Ratings
Latest news on CHUGAI PHARMACEUTICAL CO.,
02/17Chugai Pharmaceutical Co., Ltd. - Changes to Marketing Arrangements of the SG..
AQ
02/17CHUGAI PHARMACEUTICAL : Files for Additional Indications of Tecentriq and Avasti..
AQ
02/14CHUGAI PHARMACEUTICAL : Foundation Medicine and Chugai Announce Partnership with..
AQ
02/14CHUGAI PHARMACEUTICAL : Polatuzumab Vedotin Achieved Primary Endpoint in the Jap..
AQ
02/13CHUGAI PHARMACEUTICAL : Wins Second Prize for the Second Consecutive Year in the..
AQ
02/13CHUGAI PHARMACEUTICAL : Joins the Consortium of Companies Promoting Anti-Smoking..
AQ
02/10CHUGAI PHARMACEUTICAL : Supports National Cancer Center Japan for an Investigato..
AQ
02/10CHUGAI PHARMACEUTICAL CO. LTD. : - Support for Control of Novel Coronavirus
AQ
02/05CHUGAI PHARMACEUTICAL : Supports Statement of Japan Climate Initiative and Recom..
AQ
01/31CHUGAI PHARMACEUTICAL : Organizational and Personnel Changes
AQ
01/31CHUGAI PHARMACEUTICAL : Notice of Distribution of Retained Earnings
AQ
01/31CHUGAI PHARMACEUTICAL : Announces 2019 Full Year Results and Forecasts for 2020
AQ
01/31CHUGAI PHARMACEUTICAL : Notice Regarding the Difference of Individual Financial ..
AQ
01/29CHUGAI PHARMACEUTICAL : Notice Concerning Execution of Settlement Agreement on A..
AQ
01/27CHUGAI PHARMACEUTICAL CO., LTD. : annual earnings release
More news
News in other languages on CHUGAI PHARMACEUTICAL CO.,
02/21Bourse Zurich: le SMI termine dans le rouge, après avoir tenté un rebond
02/21ROCHE : Chugai obtient une nouvelle indication au Japon
02/21Bourse Zurich: le SMI toujours en baisse face au coronavirus
02/21Roche-Tochter Chugai erhält weitere Zulassung für Rozlytrek bei Lungenkrebs
02/21ROCHE : nouvelle indication pour Rozlytrek au Japon contre le cancer du poumon
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO.,
More recommendations
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO.,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 11 130,77  JPY
Last Close Price 12 255,00  JPY
Spread / Highest target 22,4%
Spread / Average Target -9,17%
Spread / Lowest Target -44,5%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Executive Officer & GM-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.0.70%60 073
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679